Sun Pharma Advanced Research Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2023

Sun Pharma Advanced Research Company Limited, an Indian clinical-stage bio-pharmaceutical company, is focused on conducting research and development (R&D) to address unmet medical needs in the fields of oncology, neurodegeneration, and immunology. The company specializes in the development of new chemical entities (NCE), new biological entities, and reformulated products. Some of its NCEs include SCC-138, SCO-088, SCO-120, and SCD-044. Additionally, the company utilizes innovative drug delivery systems such as Wrap Matrix Technology, Lipexelle technology, and TearAct Technology. Wrap Matrix technology is specifically utilized to create controlled release tablets, such as the development of Elepsia XR. Lipexelle technology is employed for ophthalmic formulations, including the creation of BAK-free latanoprost eye drops known as Xelpros, which is currently sold in the United States through a partnership with another company. Lastly, the TearAct technology has been used to develop PDP-716 eye drops for the treatment of Glaucoma.

Further information regarding the organization